Lead Author Peter Beitsch, with Drs. Paul Baron and Peter Blumencranz, on the NBRST trial with results at ASBS 2016.
Lead author, Peter Beitsch, with Drs. Paul Baron, Peter Blumencranz, on the NBRST trial with poster results at ASBS 2016.
Presented an analysis of residual cancer after Neo-Adjuvant Chemo. The luminal B, basal type and Her2 type all became less 'aggressive' on MammaPrint Index and less 'luminal' 'basal-like' and less 'Her2-like' on BluePrint. The luminal A patients did not change on either MP or BP.
Hypothesis is either 1) tumor heterogeneity, with the more aggressive clones being killed off leaving less aggressive ones behind or 2) the pressure from the chemo forced the cancer to adapt and become more resistant to therapy.